[
    [
        {
            "time": "2021-08-27",
            "original_text": "8月27日智飞生物、中国中免等12家公司公告出现利好",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "三期数据",
                    "Delta保护率",
                    "77%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "8月27日智飞生物、中国中免等12家公司公告出现利好",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-27",
            "original_text": "智飞生物：由子公司智飞龙科马与中国科学院微生物研究所合作研发的重组新型冠状",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "中科院微生物研究所",
                    "合作研发"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物：由子公司智飞龙科马与中国科学院微生物研究所合作研发的重组新型冠状",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-27",
            "original_text": "智飞生物：研发的重组新型冠状病毒疫苗获得Ⅲ期临床试验关键性数据",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "三期临床试验",
                    "关键性数据"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物：研发的重组新型冠状病毒疫苗获得Ⅲ期临床试验关键性数据",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-27",
            "original_text": "总保护效率82%、Delta保护率78% 智飞生物新冠疫苗三期临床结果出炉",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "三期临床",
                    "总保护率82%",
                    "Delta保护率78%"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "总保护效率82%、Delta保护率78% 智飞生物新冠疫苗三期临床结果出炉",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-27",
            "original_text": "权重股下行拖累大盘，机构称勿对市场波动过度解读",
            "features": {
                "keywords": [
                    "权重股",
                    "下行",
                    "拖累大盘",
                    "市场波动"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "大盘指数"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "权重股下行拖累大盘，机构称勿对市场波动过度解读",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]